^
Association details:
| Biomarker: | CD79B expression |
|---|---|
| Cancer: | T Cell Non-Hodgkin Lymphoma |
| Drug: | ARC-02 (Microtubule inhibitor, CD79b-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A CD79b Targeting ADC with Superior Anti-Tumor Activity and Safety Resulting in Significantly Improved Therapeutic Index (TI): Safe and Efficacious CD79b ADC
Published date:
11/15/2022
Excerpt:
ARC-02 was compared head-to-head to Polivy® in two different CD79b-expressing established tumor models in vivo (Granta-519 and Ramos). Single dose treatment of ARC-02 at very low payload doses induced effective and long-lasting anti-tumor responses with complete tumor eradication achieved at about half of the Polivy® payload dose in both NHL established tumor models.
DOI:
https://doi.org/10.1182/blood-2022-160056
